Project Grant R01MH144274
- This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $429,000.00 in funding to Thomas Jefferson University to conduct research on cell-type specific analysis of Src kinase-NMDA receptor complexes in schizophrenia. The goal of this 2-year project is to determine how Src kinase-mediated NMDA receptor signaling alterations are distinctly manifested in pyramidal neurons versus interneurons in the...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $433,125 Project Grant to the University of California, Los Angeles (UCLA) under the Mental Health Research Grants program (CFDA 93.242) for the period September 1, 2025 through August 31, 2027. This research project investigates inter-brain synchrony as a neural mechanism underlying social connection deficits in schizophrenia—a core symptom of the disorder that current treatments fail to address. The study will...
- Federal Grant Award Summary Vanderbilt University's Sponsored Programs Administration received a $217,818 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) effective September 9, 2025, through September 8, 2027. The project examines metabotropic glutamate receptor (mGlu) signaling mechanisms, specifically targeting Group III mGlu receptors (mGlu4/7/8) as potential therapeutic targets for schizophrenia. The...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Leland Stanford Junior University a Project Grant totaling $160,272 under the Mental Health Research Grants program (CFDA 93.242) for the period of June 1, 2025, through May 31, 2027. This research project, titled "Theta Burst Modulation of Hippocampal-Cortical Rhythms in Schizophrenia," investigates whether connectivity-guided theta burst stimulation (TBS) can alter hippocampal neural activity and...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded a Project Grant totaling $162,080 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on August 20, 2026, under the Mental Health Research Grants program (CFDA 93.242). The three-year project, with completion targeted for August 19, 2029, supports basic neuroscience research investigating cholinergic modulation of thalamocortical projections to the prefrontal cortex...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Scripps Research Institute $878,601 under the Mental Health Research Grants program (CFDA 93.242) on April 1, 2026, for a project titled "Structural Remodeling of Neural Circuits Via Multisynaptic Boutons," running through December 31, 2030. This collaborative research initiative delivers integrated neuroscience research services combining three-dimensional electron microscopy (3D-EM), chemogenetic...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of Southern California a $654,923 Project Grant (CFDA 93.242 – Mental Health Research Grants) commencing September 1, 2025, through June 30, 2030, to establish and disseminate CentileBrain, a normative modeling framework for brain health and disease. This international initiative, spearheaded by the ENIGMA (Enhancing Neuroim Genetics through Meta-Analysis) Consortium, addresses a critical gap in...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded $778,548 to the Research Foundation For Mental Hygiene, Inc. (Nathan S Kline Institute Division) on September 19, 2025, under the Mental Health Research Grants program (CFDA 93.242) to support a five-year research project examining sensory contributions to third visual pathway (TVP) dysfunction in schizophrenia. The project, extending through July 31, 2030, investigates the neural mechanisms underlying social...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of California, Los Angeles a $408,843 Project Grant under the Mental Health Research Grants program (CFDA 93.242) effective April 25, 2026, with a completion date of March 31, 2028. This award supports research investigating autonomic regulation of brain function and cognition in patients with first-episode schizophrenia and healthy control populations. The research examines how dysfunction in the...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $117,747 Project Grant to The Regents of the University of California, San Francisco under the Mental Health Research Grants program (CFDA 93.242) for the period June 1, 2026 through May 31, 2028. This K99/R00 Pathway to Independence Award supports research entitled "Functional Characterization of Schizophrenia Related Risk Genes and Variants in Neurogenesis Using Cerebral Organoids." The...
The University of Southern California received a $249,000 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), effective July 1, 2026 through June 30, 2029. This research initiative investigates the dysbindin-1–Src (sarcoma tyrosine kinase) pathway as a mechanism to restore GluN2A N-methyl-D-aspartate receptor (NMDAR) function in schizophrenia, with particular emphasis on working memory deficits. The project employs a cell-circuit-behavior approach to assess molecular, single-cell, network, and behavioral outcomes using complementary methodologies including synaptosomal co-immunoprecipitation, patch-clamp electrophysiology, multi-electrode array recording, and trace fear conditioning assays. The research will evaluate how dysfunction in the dysbindin-1–Src–GluN2A pathway contributes to impaired working memory across multiple etiologies and test whether synapse-specific Src activation (via TAT-SAPIP) restores GluN2A function. By characterizing the interactions between molecular, cellular, and circuit-level dysfunction, this work aims to identify therapeutic targets applicable across a range of molecular and genetic conditions associated with schizophrenia-related cognitive impairment.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $249.0k | 6/22/26 |